Komal Kumar Javarappa

Employment

• Linkopings universitet Medicinska Fakulteten Postdoctoral Researcher
  2013 - 2016
• University of Helsinki
  ? - 2021

Education

• University of Mysore Ph.D
  2008 - 2013

Projects & Funding

Projects & funding information is unavailable.

Publications (19)

• Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia
  Molecular oncology 2025 DOI: 10.1002/1878-0261.70130
  +Save
• Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia
  Blood 2024 DOI: 10.1182/blood-2024-207199
  +Save
• Deep Immune Profiling of Multiple Myeloma at Diagnosis and under Lenalidomide Maintenance Therapy
  Cancers 2023 DOI: 10.3390/cancers15092604
  +Save
• Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
  Blood 2023 DOI: 10.1182/blood.2021011094
  +Save
• Megakaryopoiesis impairment through acute innate immune signaling activation by azacitidine
  Journal of Experimental Medicine 2022 DOI: 10.1084/jem.20212228
  +Save
• Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets
  Leukemia 2021 DOI: 10.1038/s41375-020-01082-4
  +Save
• Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
  Science Advances 2021 DOI: 10.1126/sciadv.abe4038
  +Save
• KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia
  Leukemia 2020 DOI: 10.1038/s41375-020-0978-7
  +Save
• Dasatinib and navitoclax act synergistically to target NUP98-NSD1(+)/FLT3-ITD+ acute myeloid leukemia
  Leukemia 2019 DOI: 10.1038/s41375-018-0327-2
  +Save
• Eltrombopag Promotes Megakaryocyte Survival and Signaling in the Presence of Specific Cytotoxic Agents
  2018
  +Save